Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Hymenolepiasis

Hymenolepiasis, a neglected tropical disease, is caused by the infection of cestode species Hymenolepis diminuta and Hymenolepis nana. Our company is at the forefront of developing innovative solutions to combat Hymenolepiasis.

Overview of Hymenolepiasis

Hymenolepiasis is a zoonotic disease, affecting both humans and animals. The disease is prevalent in regions with poor sanitation and is commonly found in warm climates. The infection often goes asymptomatic but can lead to gastrointestinal symptoms, allergic responses, and in severe cases, malnutrition and developmental issues in children. The life cycle of the parasite involves both an intermediate host, typically an arthropod, and a definitive host, which can be either human or rodent.

The life cycle of Hymenolepis spp. Fig.1 Hymenolepis spp. life cycle. (Aguilar-Marcelino L., et al., 2023)

Vaccine Development for Hymenolepiasis

Proteomics-Driven Vaccine Candidates

Proteomics has been instrumental in identifying potential vaccine targets for Hymenolepiasis. By analyzing the proteins expressed by the parasite, researchers have been able to pinpoint specific antigens that elicit an immune response. For instance, heat-shock proteins (HSPs) and paramyosin have shown promise as vaccine candidates due to their immunogenic properties.

Molecular Approaches

Molecular biology techniques have facilitated the cloning and expression of these antigens. Recombinant DNA technology allows for the production of these proteins in large quantities, enabling the development of subunit vaccines. Additionally, genetic engineering has been used to create attenuated or purified vaccine formulations, enhancing safety and efficacy.

Therapeutics Development for Hymenolepiasis

Anthelmintic Drugs

The mainstay of Hymenolepiasis therapeutics remains the use of anthelmintic drugs. Praziquantel and nitazoxanide are among the most commonly used drugs for treating cestode infections. They work by disrupting the parasite's cellular structure and metabolism, leading to its death.

Albendazole has been shown to be effective against Hymenolepis nana in children. A study reported an efficacy rate of 83% for albendazole (Zentel) and 75% for albendazole (bendazol), demonstrating the drug's effectiveness in reducing the parasite load.

Alternative Therapies

Research into alternative therapies, such as the use of medicinal plants and mushroom extracts, has shown potential in combating Hymenolepiasis. For example, cinnamon extracts and Pleurotus ostreatus have demonstrated anthelmintic properties in laboratory studies.

Our Services

Drawing upon our proficiency in molecular biology and immunology, we specialize in the design and evaluation of innovative vaccines customized to target the distinct antigens of Hymenolepis parasites. In addition, our therapeutics development services focus on identifying and optimizing new anthelmintic drugs. We also explore alternative therapies, ensuring a diverse pipeline of therapeutics.

Vaccine Development

Therapeutic Development

Disease Models

Hymenolepis nana Infection Mouse Models: Mice were infected with Hymenolepis nana eggs, which then developed into adult worms within the mice.
Hymenolepis diminuta Infection Mouse Models

Hymenolepiasis, while neglected, is a disease that warrants significant attention and investment in research and development. The advancement of vaccines and therapeutics is crucial in controlling and eventually eliminating this parasitic infection. Our company is dedicated to providing cutting-edge services that accelerate the discovery and delivery of life-saving solutions. If you are interested in our services, please feel free to contact us.

References

Aguilar-Marcelino, L., et al. "Hymenolepiasis." One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan 3 (2023): 122-127.
Sulima, Anna, et al. "Identification of immunogenic proteins of the cysticercoid of Hymenolepis diminuta." Parasites & vectors 10 (2017): 1-12.
Khan, Wali, et al. "Albendazole in the treatment of Hymenolepiasis in school children." Pakistan Journal of Pharmaceutical Sciences 31 (2018).

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.